New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2013
06:32 EDTGTXIFDA designates GTx's enobosarm as Fast Track development program
GTx announced that the FDA has designated enobosarm, or GTx-024, for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer as a Fast Track development program. Fast Track status is a process designed by FDA to facilitate the development and expedite the review of new drug candidates that are intended to treat serious diseases and have the potential to fill an unmet medical need. With a Fast Track designation, there is an increased possibility for a priority review of a new drug application, or, NDA, filed for the drug candidate and more opportunity for more frequent interactions with the FDA both prior to and following the filing of a NDA.
News For GTXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
07:16 EDTGTXIGTx enters into worldwide license agreement with UTRF
GTx, Inc. announced that it has entered into an exclusive worldwide license agreement with the University of Tennessee Research Foundation, or UTRF, to develop its proprietary selective androgen receptor degrader technology which potentially can degrade and inhibit all forms of androgen receptor, including those resistant to current therapies, in patients with progressive castration-resistant prostate cancer.
April 13, 2015
17:25 EDTGTXIFormanek reports 5.1% passive stake in GTx
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use